Biosafety, bioethics and IPR

In short

Biosafety is the set of containment practices, facility designs and legal approvals that keep infectious agents and genetically engineered organisms from harming workers, the public or the environment; bioethics is the framework of principles and committees governing research on humans, animals, embryos and genetic data; IPR is the law that decides who owns a biological invention, sequence, variety or process. In India all three are statutory, not optional: the Rules, 1989 under the Environment (Protection) Act, 1986 govern every rDNA experiment, the ICMR and CPCSEA guidelines govern human and animal studies, and the Patents Act, 1970 (as amended in 2005) decides what in biology is patentable. These sections are examined in GATE BT (biosafety, bioethics and IPR appear in the "recombinant DNA technology" and allied blocks), in university "Applied Biotechnology"/"Bioethics, Biosafety and IPR" papers, and are asked directly in interviews for regulatory affairs, QA/QC, clinical research and IP-paralegal roles at Biocon, Serum Institute, Bharat Biotech, Syngene, Dr Reddy's, ICAR and CSIR labs. Compliance work is a growing entry-level career line, because a single missing IBSC approval or NBA clearance can stop a product or invalidate a patent.

Explained

Biosafety: risk groups, containment levels and practice

• Biosafety = containment of risk to people and environment. Biosecurity = protection against theft, misuse or deliberate release of agents (dual-use concern).
• Risk Groups (WHO / DBT): RG-1 unlikely to cause disease (*E. coli* K-12, *Saccharomyces*); RG-2 moderate individual, low community risk (*Salmonella*, HBV, dengue); RG-3 high individual, low community risk (*M. tuberculosis*, HIV, rabies, SARS-CoV-2 culture work); RG-4 high individual and community risk, no treatment (Nipah, Ebola, Crimean-Congo haemorrhagic fever).
• Biosafety Levels (BSL-1 to BSL-4) combine practices + safety equipment (primary barrier) + facility design (secondary barrier):
  • BSL-1: open bench, handwash sink, GLP practices, no special containment. Teaching labs.
  • BSL-2: BSL-1 plus restricted access, biohazard signage, Class II biosafety cabinet for aerosol-generating steps, autoclave in the building, PPE. Most hospital and diagnostic microbiology.
  • BSL-3: controlled access through double doors/anteroom, directional inward airflow, non-recirculated HEPA-filtered exhaust, sealed penetrations, all work in BSC, respirators, pass-through autoclave.
  • BSL-4: Class III cabinet line or positive-pressure suit, dedicated air supply/exhaust, effluent decontamination, change and shower rooms, airlocks. In India: NIV Pune (human, ICMR) and NIHSAD Bhopal (animal, ICAR).
• Primary containment devices: Class I BSC (personnel + environmental protection, no product protection — HEPA-filtered exhaust, open front), Class II A1/A2/B1/B2 (personnel + product + environment; ~70% recirculated, HEPA-filtered — the common tissue-culture/microbiology cabinet), Class III glove box (fully sealed, BSL-4).
• A laminar-flow (horizontal) clean bench protects the product, not the worker — never used for pathogens.
• HEPA filter: removes ≥99.97% of 0.3 µm particles (the most-penetrating size); ULPA ≥99.999%.
• Sterilisation/disinfection: autoclave 121 °C, 15 psi (≈103 kPa gauge), 15–20 min for loads, 30–60 min for waste; 1% sodium hypochlorite for spills; 70% ethanol for surfaces; formaldehyde/vapourised H₂O₂ for room fumigation; UV only as a surface adjunct.
• Spill drill: cover with absorbent, flood with disinfectant, wait the contact time, collect inward, autoclave, report to the Biosafety Officer.
• Waste: handled under the Bio-Medical Waste Management Rules, 2016 (amended 2018, 2019) — yellow (anatomical, soiled, lab/microbiology waste, chemical; incineration/deep burial), red (contaminated recyclable plastics; autoclave then shred/recycle), white translucent puncture-proof (sharps), blue (glassware, metallic implants). Pre-treat lab cultures on site before handing to the CBWTF.

Indian regulatory framework for GMOs

• Governing law: "Rules for the Manufacture, Use, Import, Export and Storage of Hazardous Micro-organisms / Genetically Engineered Organisms or Cells, 1989" (commonly "Rules, 1989") notified under the Environment (Protection) Act, 1986. Supported by the DBT Regulations and Guidelines for Recombinant DNA Research and Biocontainment (first 1990, revised 1994, 2017) and guidelines for confined field trials, GE insects, stem cells and genome-edited plants.
• Six-tier committee structure:
  1. RDAC — Recombinant DNA Advisory Committee (DBT): advisory, keeps policy abreast of science.
  2. IBSC — Institutional Biosafety Committee: mandatory in every institution doing rDNA work; has a DBT nominee; approves and monitors Category I/II experiments, files reports to RCGM.
  3. RCGM — Review Committee on Genetic Manipulation (DBT): approves high-risk/Category III experiments, import/export and exchange of GE material, and small-scale/confined field trials.
  4. GEAC — Genetic Engineering Appraisal Committee (MoEFCC): the apex approval body for environmental release, large-scale use and commercialisation.
  5. SBCC — State Biotechnology Coordination Committee: state-level inspection and enforcement.
  6. DLC — District Level Committee: local monitoring of field trials and releases.
• Risk categories of experiments: Category I (exempt/low, IBSC notification), Category II (IBSC approval, prior intimation to RCGM), Category III (RCGM approval before start), plus restricted experiments requiring specific clearance.
• Other regulators touching GM products: CDSCO/DCGI for rDNA pharmaceuticals (with RCGM/GEAC under the CDSCO–DBT "Guidelines on Similar Biologics", 2016), FSSAI for GM food (Food Safety and Standards Act, 2006; non-GM/GM certification is required for specified imported food consignments — the detailed GM-food regulations have been in draft/notification flux, so quote the current FSSAI notification rather than a remembered rule), PPV&FRA for varieties, NBA for access to Indian biological resources.
• Labelling: packaged food with GM ingredients must carry a "GM" declaration under the Legal Metrology (Packaged Commodities) Rules, 2011.
• India's GM crop record: Bt cotton (Bollgard) approved 2002 — the only GM crop commercially cultivated; Bt brinjal approval indefinitely held in moratorium (2010); GM mustard DMH-11 environmental release approved by GEAC in Oct 2022 but challenged — the Supreme Court delivered a split verdict in July 2024 and the matter was referred onward, so treat it as sub judice.
• Genome editing: SDN-1 and SDN-2 genome-edited plants (no foreign DNA in the final product) were exempted from Rules 7–11 of the Rules, 1989 by MoEFCC/DBT office memorandum (2022), with DBT's *Guidelines for Safety Assessment of Genome Edited Plants, 2022*; SDN-3 remains fully regulated as a GMO. ICAR announced India's first genome-edited rice lines (DRR Dhan 100 "Kamala", Pusa DST Rice 1) in 2025.

International biosafety and access instruments

• Convention on Biological Diversity (CBD), 1992 — three objectives: conservation, sustainable use, fair and equitable sharing of benefits. India is a Party.
• Cartagena Protocol on Biosafety (2000, in force 2003): transboundary movement of living modified organisms (LMOs); Advance Informed Agreement (AIA), the Biosafety Clearing House, and the precautionary approach; documentation for LMO-FFP (food, feed, processing).
• Nagoya Protocol (2010, in force 2014): access and benefit sharing (ABS) with prior informed consent (PIC) and mutually agreed terms (MAT).
• Biological Diversity Act, 2002 (amended 2023) with the Biological Diversity Rules: NBA (national), SBBs (state), BMCs (local, maintaining People's Biodiversity Registers). Section 3 restricts access by foreigners/foreign entities; Section 6 governs IP based on research on an Indian biological resource: before the 2023 amendment NBA approval was needed before *applying*; as amended, a foreign-controlled applicant needs NBA approval before the grant of the IP, while an Indian applicant must register with the NBA before grant and obtain prior approval at commercialisation (the amendment also eased obligations for registered AYUSH practitioners and cultivated medicinal plants — check the amended text and the 2024 rules for the current scope).
• Biopiracy case law: the neem patent (EPO revocation, 2000) and the turmeric wound-healing patent (USPTO re-examination, 1997) were defeated on prior art; the Basmati claims were narrowed. India's answer is the Traditional Knowledge Digital Library (TKDL), searchable by patent offices as prior art.
• Other: Biological Weapons Convention (1972, India a Party), WHO Laboratory Biosafety Manual (4th edition, 2020 — risk- and evidence-based rather than purely BSL-prescriptive), OECD GLP principles.

Bioethics: principles, committees and Indian codes

• Four principles (Beauchamp and Childress): autonomy (voluntary informed choice), beneficence (do good), non-maleficence (do no harm), justice (fair distribution of burdens and benefits). Add confidentiality and respect for persons/vulnerable groups.
• Historical codes: Nuremberg Code (1947 — voluntary consent is absolutely essential), Declaration of Helsinki (1964, periodically revised), Belmont Report (1979), CIOMS guidelines.
• Human research in India: ICMR National Ethical Guidelines for Biomedical and Health Research Involving Human Participants, 2017; every study needs clearance from a registered Institutional Ethics Committee (IEC).
• Clinical trials: the New Drugs and Clinical Trials Rules, 2019 (which superseded the Schedule Y framework) — mandatory registration of the Ethics Committee with CDSCO, registration on the CTRI before enrolment, defined timelines for approval, compensation for trial-related injury or death, and a free-medical-management obligation. ICH-GCP plus the Indian GCP guidelines govern conduct.
• Informed consent must cover purpose, procedures, risks, benefits, alternatives, confidentiality, compensation, voluntariness and the right to withdraw; documented by signature/thumb impression with an impartial witness for illiterate participants; audio-video recording is required for specified categories (e.g. vulnerable participants/new chemical entities — see the current rule).
• Animal research: Prevention of Cruelty to Animals Act, 1960 and the Breeding of and Experiments on Animals (Control and Supervision) Rules, 1998 (amended); the CPCSEA (committee under the Animal Welfare authority) registers facilities; every institution needs an IAEC with a CPCSEA nominee. Apply the 3Rs — Replacement, Reduction, Refinement; humane endpoints; approved euthanasia methods.
• Embryo, stem cell and reproduction: National Guidelines for Stem Cell Research, 2017 (ICMR–DBT) — permitted, restricted and prohibited categories; reproductive cloning and germline genetic modification for reproduction are prohibited; a 14-day limit on culturing human embryos; oversight by the institutional committee for stem cell research and the national apex committee. Also the ART (Regulation) Act, 2021, Surrogacy (Regulation) Act, 2021, PCPNDT Act, 1994 (no sex selection), Transplantation of Human Organs and Tissues Act, 1994 (amended 2011).
• Genetic data and privacy: ELSI issues from the Human Genome Project — genetic discrimination in insurance and employment, incidental findings, the right not to know, ownership of samples (*Moore v Regents*). India has no dedicated genetic non-discrimination statute comparable to the US GINA; privacy flows from the *Puttaswamy* (2017) right-to-privacy judgment and the Digital Personal Data Protection Act, 2023 (rules notified subsequently — verify current commencement dates), under which health and genetic data is personal data requiring consent and purpose limitation.
• Biosafety/bioethics flashpoints to be able to discuss: He Jiankui's germline-edited babies (2018) and the global condemnation; gain-of-function research and dual use; GM food consumer choice; terminator-gene and seed-sovereignty objections; animal use in cosmetics testing (banned in India).

IPR in biotechnology

• Forms of IP: patent (new, non-obvious, industrially applicable invention; 20 years), plant variety right (PPV&FR Act), trade secret (no statute in India — protected by contract and confidentiality), trademark (brand), copyright (software, databases, publications — Copyright Act, 1957), geographical indication (GI Act, 1999), design (shape of a device). TRIPS (1995) sets the minimum standard.
• Patentability tests: novelty (no prior publication/use anywhere), inventive step (Section 2(1)(ja) — technical advance and/or economic significance, non-obvious), industrial applicability, enabling disclosure, and not falling under Sections 3 and 4.
• Key exclusions in the Patents Act, 1970 for life sciences:
  • 3(b) — inventions contrary to public order/morality or causing serious prejudice to humans, animals, plants, health or environment.
  • 3(c) — mere discovery of a scientific principle or of a living thing or non-living substance occurring in nature (so a native gene/protein sequence as such is not patentable).
  • 3(d) — a new form of a known substance without enhancement of known efficacy (*Novartis v Union of India*, 2013, imatinib mesylate — "efficacy" read as therapeutic efficacy).
  • 3(e) — mere admixture (aggregation of properties).
  • 3(i) — methods of medical/surgical/diagnostic/therapeutic treatment of humans and animals.
  • 3(j) — plants and animals in whole or part, seeds, varieties, species and essentially biological processes.
  • 3(p) — traditional knowledge or aggregation of known properties.
  • Section 4 — no patent for inventions relating to atomic energy.
• What IS patentable in biotech in India: isolated/engineered micro-organisms and cell lines (allowed after the 2002 amendment), recombinant vectors, plasmids and transformed host cells, recombinant proteins and processes of making them, vaccines and formulations, diagnostic kits/devices, bioprocesses and fermentation methods, and processes with a living end product (Dimminaco AG v Controller of Patents, Calcutta HC, 2002 — a process for a bursitis vaccine with live virus end product).
• Procedure (India): provisional or complete specification (Form 1, 2) → 12 months to file the complete → publication at 18 months from filing/priority → Request for Examination (the Patents (Amendment) Rules, 2024 reduced the deadline to 31 months from priority; it was 48 months earlier) → First Examination Report → reply within the prescribed period → pre-grant opposition (Section 25(1), by any person) → grant → post-grant opposition (Section 25(2), within 1 year) → renewal fees from the 3rd year, term 20 years from the filing date (or from the international filing date for a PCT national-phase case).
• Biotech-specific filing duties: deposit of biological material at an International Depositary Authority under the Budapest Treaty (India acceded in 2001; Indian IDAs include MTCC, IMTECH Chandigarh and NCMR, NCCS Pune) with the accession number in the specification; mandatory disclosure of source and geographical origin of biological material (non-disclosure or wrongful mention is a ground of opposition/revocation); NBA approval where an Indian biological resource is involved; sequence listings in the prescribed electronic format.
• Post-grant flexibilities: compulsory licence under Section 84 after 3 years from grant if reasonable requirements of the public are unmet, the price is not reasonably affordable, or the patent is not worked in India (Natco v Bayer, 2012, sorafenib — licence at 6% royalty on net sales); government use (Section 100), Bolar/research exemption (Section 47 and 107A), parallel import.
• PPV&FR Act, 2001: registers new, extant, essentially derived and farmers' varieties on DUS (distinctness, uniformity, stability) testing; protection is 15 years for crops (18 years for trees and vines), and 15 years from notification for extant varieties; strong Farmers' Rights — a farmer may save, use, sow, re-sow, exchange and sell farm produce of a protected variety, but not sell branded seed of it; also a National Gene Fund and benefit-sharing. India chose this *sui generis* route instead of joining UPOV.
• Routes abroad: PCT (international application, 30/31-month national phase), Paris Convention priority (12 months), EPO/USPTO national filings. Compare jurisdictions: *Diamond v Chakrabarty* (US, 1980) — a living engineered bacterium is patentable; *Myriad Genetics* (US, 2013) — isolated genomic DNA is not patentable, cDNA is; the EPO allows micro-organisms and biotech processes with Rule 28 morality exclusions. India is more restrictive than both.
• Biologics and exclusivity: biosimilars follow the CDSCO–DBT Guidelines on Similar Biologics (2016 revision) — comparability in quality, non-clinical and clinical terms; India has no data exclusivity regime, unlike the US BPCIA 12-year period.

Key points

• Rules, 1989 - the operative GMO law in India, notified under the Environment (Protection) Act, 1986.
• Six committees - RDAC (advice), IBSC (institution), RCGM (DBT approval), GEAC (environmental release), SBCC (state), DLC (district).
• Risk Group ≠ BSL - the group classifies the agent; the level classifies the facility and practice for the specific procedure.
• BSL-3 signature - directional inward airflow with HEPA-filtered, non-recirculated exhaust; BSL-4 - suit or Class III line plus effluent decontamination.
• Class II BSC protects worker, product and environment; a horizontal laminar bench protects only the product.
• HEPA - ≥99.97% retention of 0.3 µm particles; tested by DOP/PAO challenge.
• Autoclave standard - 121 °C, 15 psi, 15–20 min; waste loads longer; validated with *Geobacillus stearothermophilus* spore strips.
• BMW Rules, 2016 - yellow/red/white/blue segregation; lab cultures are yellow-category and pre-treated on site.
• Cartagena Protocol - AIA procedure, Biosafety Clearing House, precautionary approach for LMO movement.
• Biological Diversity Act, 2002 (amd. 2023) - NBA/SBB/BMC; IP on Indian biological resources needs NBA approval (foreign-controlled applicants) or NBA registration (Indian applicants) before grant.
• Four bioethics principles - autonomy, beneficence, non-maleficence, justice.
• New Drugs and Clinical Trials Rules, 2019 - registered Ethics Committee, CTRI registration, compensation for trial injury.
• CPCSEA and IAEC - mandatory for animal experiments; apply the 3Rs.
• Stem cell guidelines, 2017 - reproductive cloning and reproductive germline modification are prohibited; 14-day embryo culture limit.
• Section 3(j) - plants, animals, seeds, varieties and essentially biological processes are not patentable in India; micro-organisms are.
• Section 3(d) - a new form of a known substance needs enhanced therapeutic efficacy (Novartis, 2013).
• Patent term - 20 years from filing; publication at 18 months; renewal from the 3rd year; RFE within 31 months of priority (2024 Rules).
• PPV&FR Act - 15 years for crops, 18 for trees/vines, with statutory Farmers' Rights; Budapest Treaty deposit covers the microorganism disclosure requirement.

Formulas and examples

1. Autoclave cycle validation (log reduction and F₀). A waste load carries 1 × 10⁸ CFU of spores per litre; the spore D₁₂₁ = 1.5 min. For a 10⁻⁶ SAL the required reduction is from 10⁸ to 10⁻⁶ = 14 logs.

• Time at 121 °C = D₁₂₁ × LR = 1.5 × 14 = 21 min of holding at temperature (F₀ = 21 min).
• A 15-min hold gives LR = 15/1.5 = 10 logs → survivors = 10⁸ × 10⁻¹⁰ = 10⁻² per litre, i.e. SAL 1 in 100 — not acceptable, so the cycle must be extended to ≥21 min plus heat-up/penetration time.

2. BSL-3 room ventilation and pressure cascade. Room 6.0 m × 5.0 m × 3.0 m = 90 m³; exhaust fan removes 1,800 m³/h; supply is 1,620 m³/h.

• ACH = 1,800 / 90 = 20 air changes per hour (BSL-3 designs commonly target 10–20).
• Net extract = 1,800 − 1,620 = 180 m³/h, which maintains inward airflow; with an anteroom gradient of about −30 Pa relative to the corridor, the lab is the most negative space.
• Decay time for a 90% (1-log) clearance of an aerosol at 20 ACH ≈ (ln 10 / 20) × 60 ≈ 7 min, so a 15-min wait after a spill clears ~2 logs.

3. Biosafety cabinet inflow and HEPA performance. A Class II A2 cabinet has a sash opening 1.20 m × 0.20 m.

• A = 1.20 × 0.20 = 0.24 m²; at the specified inflow velocity of 0.5 m/s, inflow = 0.5 × 0.24 = 0.12 m³/s = 432 m³/h.
• If 70% of air is recirculated, the exhaust to the room/duct = 0.30 × total downflow; both exhaust and downflow pass a HEPA filter.
• Penetration of one HEPA = 100 − 99.97 = 0.03%. Two HEPA stages in series: 0.0003 × 0.0003 = 9 × 10⁻⁸ → efficiency 99.99999%.

4. Disinfectant preparation. You need 10 litres of 1% (w/v) available chlorine from a 5% sodium hypochlorite stock.

• C₁V₁ = C₂V₂ → 5 × V₁ = 1 × 10 → V₁ = 2 L stock + 8 L water. Contact time 10 min for a blood/culture spill (1% for high-risk spills, 0.5% for routine surfaces); prepare fresh daily because hypochlorite decays.

5. Patent term, fees and a compulsory-licence royalty. A complete specification is filed on 14 March 2022 claiming a recombinant vaccine process.

• Publication at 18 months → about 14 September 2023; RFE due within 31 months of the priority date → about October 2024; term ends 14 March 2042 if renewals are paid; the first renewal fee is for the 3rd year and falls due before the 2nd year ends, i.e. before 14 March 2024 (fees that fall due before grant may be paid within three months of the grant being recorded).
• Indicative official fees (e-filing): a natural person or startup pays ₹1,600 for the application and ₹4,000 for the RFE, a small entity ₹4,000 and ₹10,000, and any other (large) entity ₹8,000 and ₹20,000; physical filing costs 10% more — fee schedules are revised periodically (the Patents (Amendment) Rules, 2024 changed several), so always check the current First Schedule.
• If the patent is later subject to a compulsory licence at 6% of net sales (the *Natco v Bayer* rate) and the licensee's net sales are ₹25 crore, royalty = 0.06 × 25,00,00,000 = ₹1.5 crore.

Where it is used

• Vaccine and biologics manufacturing (Serum Institute, Bharat Biotech, Biological E, Biocon): BSL-2/3 suites, GEAC/RCGM dossiers, GLP/GMP documentation, similar-biologics filings with CDSCO.
• Clinical research and CRO work (Syngene, Lambda, Veeda, hospital CTUs): IEC submissions, informed-consent documents, CTRI registration, safety reporting under the 2019 Rules.
• Diagnostic and hospital labs under NABL/ICMR: BSL-2 practice, BMW Rules segregation, biosafety officer and spill-response roles; ICMR network VRDLs for RG-3 agents.
• Agricultural biotech and seed companies (Mahyco, Rasi, Nuziveedu, ICAR institutes): confined field-trial permits, DLC/SBCC monitoring, PPV&FR variety registration, Bt refuge and stewardship compliance.
• IP practice and technology transfer: patent drafting and FTO searches in CSIR-URDIP/TIFAC, university TTOs, Budapest Treaty deposits at MTCC Chandigarh or NCMR Pune, NBA applications for bioresource-based inventions.
• Regulatory affairs and QA roles: preparing RCGM/GEAC, CDSCO and FSSAI submissions — one of the most common first jobs for a biotech graduate who knows these rules.

Interview questions

• Q: Difference between a Risk Group and a Biosafety Level? A: The Risk Group classifies the hazard of the organism itself; the Biosafety Level is the combination of practices, containment equipment and facility design used for a particular procedure with it — a risk assessment can require BSL-3 practices for an RG-2 agent if large volumes or aerosols are involved.
• Q: Which body gives final approval for commercial release of a GM crop in India? A: The Genetic Engineering Appraisal Committee (GEAC) under the Ministry of Environment, Forest and Climate Change, after RCGM-cleared confined trials and biosafety data.
• Q: Can you patent a gene sequence in India? A: Not a naturally occurring sequence — Section 3(c) excludes discovery of a living thing or substance occurring in nature; but an engineered construct, a recombinant vector, a transformed micro-organism or a process using the sequence can be patented.
• Q: Why are plants and animals not patentable in India while micro-organisms are? A: Section 3(j) excludes plants, animals, seeds, varieties and essentially biological processes; the 2002 amendment and the Dimminaco decision opened the door to micro-organisms and processes with living end products. Plant varieties are protected instead under the PPV&FR Act.
• Q: What is Section 3(d) and which case defined it? A: It bars patents on new forms of known substances without enhanced known efficacy; *Novartis v Union of India* (2013) held that for a medicine "efficacy" means therapeutic efficacy, so the beta-crystalline salt of imatinib was refused.
• Q: Why deposit a micro-organism under the Budapest Treaty? A: A written description cannot enable someone to reproduce a strain, so depositing it with an International Depositary Authority and citing the accession number satisfies the enablement requirement in all member states with one deposit.
• Q: What does the Cartagena Protocol require before a first transboundary shipment of an LMO for release? A: Advance Informed Agreement — the exporter notifies and the importing Party decides on the basis of a risk assessment, with the decision posted to the Biosafety Clearing House.
• Q: What must an informed consent document contain? A: Purpose, procedures and duration, foreseeable risks and benefits, alternatives, confidentiality arrangements, compensation and treatment for injury, contact details, and a clear statement that participation is voluntary and may be withdrawn without penalty.
• Q: What are the 3Rs and who enforces them in India? A: Replacement, Reduction and Refinement of animal use; enforced through CPCSEA registration and the Institutional Animal Ethics Committee with its CPCSEA nominee, under the Prevention of Cruelty to Animals Act, 1960 and the 1998 Rules.
• Q: A collaborator abroad wants an Indian soil isolate for screening. What approvals do you need? A: NBA approval under the Biological Diversity Act for access and benefit sharing (and, for any IP on it, NBA approval or registration before grant), RCGM clearance for the export/exchange of the material, plus a material transfer agreement and shipping as per IATA/import-permit rules.
• Q: How does a compulsory licence work? A: Under Section 84, three years after grant any person may apply if the public's reasonable requirements are unmet, the price is unaffordable, or the invention is not worked in India; the Controller may grant a licence on terms including a royalty, as in *Natco v Bayer* at 6% of net sales.
• Q: Are SDN-1 genome-edited plants regulated as GMOs in India? A: SDN-1 and SDN-2 edits that leave no foreign DNA were exempted from Rules 7–11 of the Rules, 1989 by a 2022 government memorandum, and are assessed under the 2022 genome-edited plant guidelines; SDN-3 edits remain fully regulated.

Common mistakes

• Writing "BSL-2 organism" or equating Risk Group 3 with BSL-3 automatically — the level follows the risk assessment of the procedure, not just the agent.
• Saying a horizontal laminar-flow bench gives personnel protection, or working with pathogens in one.
• Confusing the committees: IBSC is institutional, RCGM sits in DBT and clears experiments and trials, GEAC in MoEFCC clears environmental release. Students routinely attribute field-trial clearance to GEAC alone.
• Claiming "genes and plants are patentable in India like in the US" — Sections 3(c) and 3(j) and the Myriad/Chakrabarty contrast are exactly where interviewers probe.
• Taking the patent term as 20 years from grant or from publication; it runs from the filing (or international filing) date, with renewals from the 3rd year.
• Forgetting the NBA/Section 6 approval and the disclosure of source of biological material — omission is a ground for opposition and revocation, and is the classic biopiracy failure.
• Mixing up ethics approvals: IEC for humans, IAEC/CPCSEA for animals, IBSC for rDNA, and the stem-cell committee for embryonic work; and treating consent as a signature exercise rather than a documented process.
• Quoting Schedule Y, the old 48-month RFE deadline or a remembered fee figure — these have been superseded by the New Drugs and Clinical Trials Rules, 2019 and the Patents (Amendment) Rules, 2024.

Related topics

Medical biotechnology: vaccines and biologics · Agricultural biotechnology · Environmental biotechnology · Genomics and proteomics · Bioinformatics basics · Bioprocess validation, GMP and GLP